ArticleDrugs2012
Advances in drug development for acute migraine.
Article in Drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Trends in Triptan Usage in Korea: A Population-Based Cohort Study.Journal of Korean medical science · 2024Article
- The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.The journal of headache and pain · 2019Review
- Review
- Review
- Acute Treatment of Migraine.Noro psikiyatri arsivi · 2013Review
- Ophthalmic beta blockers: treatment for acute migraine?Missouri medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triptans revolutionized medical recognition and the acute treatment of migraine. Yet, throughout a lifetime, millions of patients who live with migraine endure hundreds of days of disability due to their disease. Most migraine attacks respond to migraine-specific interventions, but attack response does not predict patient response. Generally, migraine patients respond to acute treatment for some, but not necessarily all, attacks of migraine. Consequently, there remains a substantial unmet clinical need for better acute treatment of migraine. Numerous avenues of research and clinical observation provide insight into potential advances in acute treatment of migraine. These include better delivery systems for existing drugs, as well as the development of potential new therapeutic agents. In addition, new changes in migraine taxonomy and clinical observations of migraine suggest additional important therapeutic opportunities. Based on clinical observations, this article explores future acute treatment needs, drugs in development for acute migraine, and new products that deliver established drugs to improve treatment response.
Indexed as
Identifiers
23116251What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.